Advertisement

Prospective carriers of 223Ra for targeted alpha particle therapy

  • J. Kozempel
  • M. Vlk
  • E. Málková
  • A. Bajzíková
  • J. Bárta
  • R. Santos-Oliveira
  • A. Malta Rossi
Article

Abstract

We report here on basic aspects that have to be addressed in TAT systems and describe our experiments with prospective carriers of 223Ra intended for bone therapy based on hydroxyapatite nanoparticles. Preparation, in vitro stability tests are described. Labelling yields were ranging between 60–99 % depending on the reaction conditions. Preliminary static stability tests of successfully 223Ra-labelled hydroxyapatite nanoparticles were performed in a physiological saline and showed relatively low activity washout within 24 h (<5 % of total sample activity).

Keywords

223Ra Radium Hydroxyapatite Carriers Targeted alpha therapy TAT 

Notes

Acknowledgments

This work was partially supported by the Ministry of Education Youth and Sports of the Czech Republic, grant No.: LK21310, Technological Agency of the Czech Republic Grant No.: TA03010027 and Czech Technical University Grant No.: SGS14/084/OHK4/1D/14.

References

  1. 1.
    European Pharmacopoeia (2014) European medicine agency, London. http://www.ema.europa.eu. Accessed 25 May 2014
  2. 2.
    Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, Rondinone AJ, Standaert RF, Mirzadeh S (2011) Bioconj Chem 22:766–776CrossRefGoogle Scholar
  3. 3.
    Wang G, deKruijff RM, Rol A, Thijssen L, Mendes E, Morgenstern A, Bruchertseifer F, Stuart MCA, Wolterbeek HT, Denkova AG (2014) Appl Radiat Isot 85:45–53CrossRefGoogle Scholar
  4. 4.
    Chang M-Y, Seideman J, Sofou S (2008) Bioconj Chem 19:1274–1282CrossRefGoogle Scholar
  5. 5.
    Patel N, Gibson IR, Ke S, Best M, Bonfield W (2001) J Mater Sci Mater Med 12:181–188CrossRefGoogle Scholar
  6. 6.
    Blower PJ, Green M, Jaureghi-Osoroko M, Torres Martin de Morales R, Williamson P (2011) PCT WO 2011/151631 A1Google Scholar
  7. 7.
    Albernaz MdeS, Ospina CA, Malta Rossi A, Santos-Oliveira R (2014) Art Cells Nanomed & Biotech 42(2:):88–91CrossRefGoogle Scholar
  8. 8.
    Ziegler JF (2008) SRIM-2008 code, http://www.srim.org. Accessed 25 May 2014
  9. 9.
    Akao M, Aoki H, Kato K (1981) J Mater Sci 16:809–816CrossRefGoogle Scholar
  10. 10.
    Jarcho M, Bolen CH, Thomas MB, Bobick J, Kay JF, Doremus RH (1976) J Mater Sci 11:2027–2035CrossRefGoogle Scholar
  11. 11.
    Guseva LI, Tikhomirova GS, Dogadkin NN (2004) Radiochemistry 46:58–62CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2014

Authors and Affiliations

  • J. Kozempel
    • 1
  • M. Vlk
    • 1
  • E. Málková
    • 1
  • A. Bajzíková
    • 1
  • J. Bárta
    • 1
  • R. Santos-Oliveira
    • 2
  • A. Malta Rossi
    • 3
  1. 1.Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical EngineeringCzech Technical University in PraguePrague 1Czech Republic
  2. 2.Laboratory of NanoradiopharmaceuticalsInstitute of RadiopharmacyRio De JaneiroBrazil
  3. 3.Departamento de MateriaisCentro Brasileiro de Pesquisa FísicaRio De JaneiroBrazil

Personalised recommendations